GTBP
GT Biopharma·NASDAQ
--
--(--)
--
--(--)
7.54 / 10
Outperform
Money flow analysis registers a robust 7.54/10, suggesting strong fund inflow characteristics. However, the trend analysis shows negative trends across all scales (overall, block, Small, Medium, Large, Extra-large), with inflow ratios around 0.46-0.48. This discrepancy implies that while absolute inflows are high, the directional bias is still negative, complicating the interpretation. No analyst coverage data is available to supplement this view.
Fund Flow Rating
Is money flowing into or out of GTBP?
- GTBP holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 7.54/10 (Outperform).
